Cardiac Safety
5
min read
Why Cardiac Safety Matters More Than Ever in Modern Clinical Trials
Cardiac safety in clinical trials is the systematic assessment of a drug's effect on cardiac rhythm, on repolarization measured through the QT interval, and on cardiac structure and function across the development lifecycle. It used to be concentrated in a single thorough QT study. Since the ICH E14/S7B Questions and Answers reached Step 4 in February 2022, the assessment starts earlier and runs longer, combining centralized ECG, Holter and imaging data to surface proarrhythmic and cardiotoxic risk before it becomes a late-stage problem.
For most of the 2000s, cardiac safety had a predictable place in drug development. A thorough QT study was scheduled around the end of Phase I, and the result either cleared the path forward or forced an uncomfortable conversation. Serious work, but isolated: one study, one endpoint, one moment in the program.
That model no longer matches the pipeline. Oncology compounds carry cardiotoxicity risks a QT measurement was never designed to detect. Cell and gene therapies raise structural questions that persist for years after dosing. And the ICH E14/S7B Questions and Answers, signed off at Step 4 on 21 February 2022, set out to reduce the need for standalone thorough QT studies by letting nonclinical and early clinical data carry more weight. Cardiac safety has become a continuous discipline rather than a scheduled test, which moves a decision that once sat with regulatory affairs into the center of protocol design.
What Cardiac Safety Means in a Modern Clinical Trial
Cardiac safety in clinical trials is the structured evaluation of whether an investigational product affects the heart in ways that could harm participants during the study or patients after approval. It covers three separate questions. Does the drug disturb cardiac rhythm? Does it delay ventricular repolarization? Does it damage cardiac structure over time? Each has its own modality, its own timeline, its own regulatory literature. Programs that treat cardiac safety as a single line item tend to discover the distinction late, when fixing it is expensive.
The three pillars: rhythm, repolarization, structural and functional integrity
Rhythm assessment looks for arrhythmia and conduction delay. Repolarization assessment focuses on the QT interval and its rate-corrected forms, since a prolonged QTc is the accepted surrogate marker for proarrhythmic risk, torsade de pointes in particular. Structural assessment asks a slower question: is the myocardium being damaged, and would anyone notice inside the observation window of the study?
They do not run on the same clock. Repolarization risk declares itself in weeks. Structural toxicity can take years, which is exactly why it gets under-planned.
Pillar | What it assesses | Typical modality | Where it usually matters most |
|---|---|---|---|
Rhythm | Arrhythmia, conduction abnormalities, significant bradycardia or tachycardia | 12-lead ECG, Holter monitoring, event monitoring, telemetry | Early phase, and any compound with a known conduction signal |
Repolarization (QT/QTc) | QT prolongation and proarrhythmic potential, including torsade de pointes risk | 12-lead ECG with centralized QT measurement, concentration-QT modeling, hERG assay | First-in-human through to registration |
Structure and function | Ventricular dysfunction, reduced ejection fraction, myocarditis, fibrosis | Echocardiography, cardiac MRI, cardiac biomarkers | Oncology, cell and gene therapy, long-duration programs |
Why Cardiac Safety Matters More Than Ever: Four Shifts
Four changes explain why cardiac safety monitoring has moved up the agenda. None is new on its own. Together they redefine what an acceptable safety package looks like.
New modalities, new risks
The QT-centric model was built around small molecules acting on ion channels. Much of the current pipeline does not behave that way. Anthracyclines and HER2-targeted agents carry documented risks of ventricular dysfunction. Immune checkpoint inhibitors are associated with myocarditis that is rare but severe. GLP-1 receptor agonists show a modest but consistent increase in heart rate, which matters in cardiometabolic populations studied over years. Cell and gene therapy adds cytokine-mediated effects and long follow-up obligations.
A protocol that assesses only QT in any of these settings is measuring the wrong thing carefully.
Regulatory expectations beyond the standalone TQT
ICH E14 covers the clinical evaluation of QT/QTc prolongation, ICH S7B the nonclinical evaluation. Both reached Step 4 in May 2005 and were issued by the FDA that October. For roughly fifteen years they were applied in parallel.
The 2022 Questions and Answers changed that relationship, allowing a negative nonclinical package, an in vitro hERG assay combined with an in vivo QT study, to carry more evidentiary weight clinically. Its stated objectives include decreasing the need for thorough QT studies and informing decisions where one cannot reasonably be performed.
The practical consequence is easy to miss. Removing a dedicated study does not remove the requirement. It transfers the burden of proof onto early-phase data never collected with regulatory-grade ECG quality in mind.
Decentralized and digital data capture change the safety workflow
ECGs are increasingly collected outside the clinic visit, through hybrid designs, home nursing and connected devices. Good for retention, harder on standardization: more collection points mean more device models, more operators, more variation in electrode placement. Consumer-grade recordings and clinical-grade digital ECGs are not interchangeable for a regulated endpoint, and the difference surfaces at analysis rather than at design.
Data integrity is now a cardiac safety issue
ALCOA+ principles apply to cardiac data with unusual force: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available. A QT interval is a measurement of a few hundred milliseconds. An unverifiable device clock, a collection mistimed against the pharmacokinetic sample, an unreadable trace: none of these degrade the data point. They remove it. In a concentration-QT analysis, a handful of removed points weakens the model the whole strategy rests on.
From the Thorough QT Study to Lifecycle Cardiac Safety
What the thorough QT study was, and its limits
The thorough QT study was a dedicated trial, usually in healthy volunteers, comparing therapeutic and supratherapeutic doses against placebo and a positive control, most often moxifloxacin. It answered one question with confidence: does this compound cause QT prolongation beyond the regulatory threshold of concern?
It answered it well. The limits were structural. Expensive, late in Phase I, silent on the other two pillars, and negative in the overwhelming majority of cases.
Concentration-QT and the integrated, early-phase approach
Concentration-QT analysis models the relationship between plasma drug concentration and change in QTc, instead of comparing group means at fixed time points. Because it uses exposure directly, it can be embedded in ascending dose studies a program is running anyway.
The trade-off is operational. C-QT requires ECG collection tightly synchronized with pharmacokinetic sampling, with reliable timestamps and consistent recording conditions across sites. Sponsors are moving a regulatory-grade measurement into Phase I, where the discipline of a dedicated study does not automatically exist. Integrated strategies quietly succeed or fail there.
The Role of a Centralized Cardiac Core Lab
Why centralized reads beat site-by-site interpretation
In cardiac safety clinical trials, the reading convention matters as much as the recording device. QT measurement is more subjective than its precision suggests. Where the T wave ends, which lead to measure, how to handle a noisy beat: these are judgment calls, and readers make them differently. Automated algorithms embedded in ECG machines vary by manufacturer and were never built for regulatory endpoint analysis.
Spread that across forty sites in twelve countries and measurement variability starts competing with the drug effect. Centralized reading does not eliminate variability. It makes it consistent, which is what statistical analysis requires: one convention, blinded and trained readers, documented quality control.
What a cardiac core lab actually delivers
Reading is the visible part of a longer chain. An ECG core lab typically covers:
Equipment provisioning, configuration and site training before enrollment opens
Standardized acquisition protocols: electrode placement, resting period, collection windows
Centralized over-read by trained analysts, with cardiologist review of abnormal findings
Consistent application of the QTc correction method across the study
Query management, reconciliation with the clinical database, audit-ready traceability
Submission-ready datasets, including preparation for the FDA ECG Warehouse
Statistical analysis and medical writing for the cardiac safety sections of the submission
Designing Cardiac Safety Into Your Protocol: A Practical Checklist by Banook
Most cardiac safety problems are design problems that surfaced late. Run this before the protocol is finalized.
Name the pillars. State which of rhythm, repolarization and structural risk the program addresses, and why the others are excluded.
Test the nonclinical package early. Establish whether hERG and in vivo QT results support a reduced clinical QT strategy under the E14/S7B Q&As, before Phase I is designed.
Synchronize ECG and PK. If concentration-QT is planned, timing precision matters more than volume. Specify collection windows relative to PK sampling in the protocol itself.
Fix the correction method in advance. Bazett, Fridericia or a study-specific correction, chosen before seeing the data and documented.
Write a cardiac safety charter. Reading conventions, blinding, adjudication rules, alert thresholds and escalation path, before enrollment.
Standardize every collection point. Same device configuration, same training, same acquisition protocol, including home-based visits.
Plan the submission format from day one. Retrofitting a dataset to FDA ECG Warehouse expectations at database lock is avoidable work.
Define the medical review path. Who reads what, in what timeframe, and what triggers cardiologist escalation.
Banook has worked on this problem since 1999, when the group was founded as Cardiabase, a core lab dedicated to cardiac safety. The board-certified cardiologists who oversee the reads also take part in protocol review, so reading conventions and the charter are settled before the first ECG is collected rather than reconstructed afterwards. Digital ECGs, paper ECGs, Holter recordings and extracted ECGs are centralized on a platform developed in house and aligned with 21 CFR Part 11, so non-standard designs are handled through configuration rather than a custom build. QT analysis covers QTcB, QTcF and QTcL, and submission support extends to the FDA ECG Warehouse.
Review the full cardiac safety offering or talk to the team about a specific protocol.